Clinical trials: Cognitive Decline in Older Adults
Age Related Cognitive Decline
Improvements in Cognitive Skills of Older Adults Using Dynamic Visual Attention Training
The proposed SBIR Phase I study tests the feasibility of PATH neurotraining for improving cognitive skills in older adults and, potentially, forestalling or protecting against cognitive decline and dementia.
- Trial name
- NCT03456986
- Testing
- PATH neurotraining, Orientation Discrimination
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Perception Dynamics Institute
Cognitive Decline
A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive Decline
This is a multi-center, double-blind, randomized, placebo-controlled study to determine the safety, tolerability, and pharmacodynamics of SDI-118 in a once daily (QD) dosing regimen on elderly male and female study participants…
- Trial name
- NCT05199142
- Testing
- SDI-118
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 5 people
- Sponsor
- Syndesi Therapeutics
Alzheimer Disease, Cognitive Decline
Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's Disease
The investigators will study performance on computerized cognitive tasks in healthy participants of different ages to gather normative data for newly developed computerized cognitive tests.
- Conditions
- Alzheimer Disease, Cognitive Decline, Aging
- Trial name
- NCT04800588
- Testing
- California Cognitive Assessment Battery
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Neurobehavioral Systems, Inc.
Mild Cognitive Impairment
Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)
Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)
- Trial name
- NCT06347315
- Testing
- BrainXpert
- Where
- 28 sites in France, Germany and 4 more
- Volunteers
- 380 people
- Sponsor
- Société des Produits Nestlé (SPN)
Down Syndrome, Cognitive Dysfunction
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17
The purpose of this study is to determine the efficacy and safety of donepezil hydrochloride (Aricept) in the treatment of the cognitive dysfunction shown by children with Down syndrome, aged 11 to 17.
- Trial name
- NCT00754052
- Testing
- Aricept (donepezil hydrochloride)
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Eisai Inc.
Down Syndrome (Trisomy 21)
AEF0217 in Participants With Down Syndrome
The goal of this clinical trial is to identify if AEF0217 show an improvement in adaptive behaviors (daily life activities) in adults and older adolescents with Down Syndrome. It will also learn about the safety of AEF0217.
- Trial name
- NCT07334912
- Testing
- AEF0217 100 µg, AEF0217 300 µg
- Where
- 10 sites in France, Italy and 1 more
- Volunteers
- 188 people
- Sponsor
- Aelis Farma
Mild Cognitive Impairment
Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.
Glutamate is fundamentally involved in learning and memory. Memory loss associated with mild cognitive impairment may be due to loss of glutamate receptors in the aging brain.
- Trial name
- NCT00040443
- Testing
- CX516
- Where
- 8 sites in United States
- Volunteers
- 175 people
- Sponsor
- RespireRx
Aging, Cognitive Change
Test and Usability of Mixed-reality Screening Tool for Early Detection of Cognitive Declines
The aim of this study as part of the SCOBES-AR project is to establish and test a protocol for implementation and usability of mixed reality-enhanced multidisciplinary screening tool for early detection of cognitive impairments…
- Trial name
- SCOBES-AR (NCT05403814)
- Testing
- observational screening procedure (no intervention)
- Where
- Austria
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- FH Joanneum Gesellschaft mbH
Alzheimer Disease, Dementia
ADVANCE Study: Alzheimer Disease eVAluation iN Clinical PracticE
In 1906, Dr. Alois Alzheimer first described the disease that later took his name. Today, 100 years later, 24 million people worldwide suffer from Alzheimer's disease or other dementias.
- Conditions
- Alzheimer Disease, Dementia, Cognitive Disorders
- Trial name
- ADVANCE (NCT01772095)
- Where
- Greece
- Volunteers
- 389 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Down Syndrome, Cognitive Dysfunction
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10
The purpose of this study is to determine the efficacy and safety of donepezil hydrochloride (Aricept) in the treatment of cognitive dysfunction shown by children with Down syndrome, aged 6 to 10 years.
- Trial name
- NCT00754013
- Testing
- Aricept (Donepezil hydrochloride)
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Eisai Inc.
Age-Related Cognitive Decline, Age-Related Memory Disorders
Memory Improvement With Docosahexaenoic Acid Study (MIDAS)
The purpose of this study is to investigate the effect of docosahexaenoic acid (DHA, 22:6n-3) in improving cognitive functions in subjects with age-related cognitive decline.
- Trial name
- MIDAS (NCT00278135)
- Where
- 14 sites in United States
- Volunteers
- 485 people
- Sponsor
- dsm-firmenich Switzerland AG
Anxiety, Depression
Comparison of MMFS Dosages in Older Adults
This study is designed to compare the effectiveness of different doses of brain health supplement MMFS relative to placebo on cognition, mood, and sleep quality.
- Conditions
- Anxiety, Depression, Sleep Quality, Cognitive Impairment
- Trial name
- NCT03601169
- Testing
- Low Dose MMFS-205-SR, High Dose MMFS-205-SR
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Neurocentria, Inc.
Cognition Disorder, Nervous System Diseases
A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment
The purpose of this follow-up study is to assess the long-term safety and tolerability of galantamine in individuals with mild cognitive impairment who participated in a previous study with galantamine
- Conditions
- Cognition Disorder, Nervous System Diseases, Mental Disorders, Brain Diseases
- Trial name
- NCT00240695
- Testing
- galantamine hydrobromide
- Volunteers
- 724 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Insomnia, Insomnia Chronic
Deep Sleep in Older Adults
This double blind randomized clinical trial on older independent-living healthy individuals with symptoms of insomnia will harness Cognitive Behavioral Therapy for Insomnia (CBT-I) and augment it with ambulatory data collection…
- Trial name
- NCT07316153
- Testing
- SleepSpaceRx CBT-I-IoT-AI, SleepEZ CBTi, Sleep Hygiene IoT
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- Proactive Life Inc
Cognition Disorders in Old Age
Study on the Effectiveness and Safety of Two Olive Extract- Based (Olea Europea L. Folium) Supplements, Alone or Combined With a Mullein Extract (Verbascum Thapsus L. Herba Cum Floribus), for the Maintenance of Cognitive Function.
The goal of this clinical trial is to learn if two food supplements based on olive leaf extract, alone or combined with mullein extract, help maintain cognitive function in older adults with mild cognitive impairment (MCI).
- Trial name
- NCT07586410
- Testing
- ACTIVE TREATMENT 1 - OLI-COGNITIVE FOOD SUPPLEMENT, ACTIVE TREATMENT 2 - OLI-VERB-COGNITIVE FOOD SUPPLEMENT
- Where
- Italy
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- ISTITUTO FARMOCHIMICO FITOTERAPICO: EPO SRL
Cognitive Decline, Cognitive Deficit
Validation Study SCOBES-AR
Purpose of the study The purpose of this study is to evaluate five tests to see if they are suitable for the early detection of cognitive impairment in people over the age of 60.
- Conditions
- Cognitive Decline, Cognitive Deficit, Cognitive Impairment
- Trial name
- NCT04204239
- Where
- Austria
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- FH Joanneum Gesellschaft mbH
Schizophrenia, Cognition Disorders
The Effect of Nicotine on Arousal, Cognition and Social Cognition in Young and Elderly Healthy Subjects.
This study in young and elderly healthy subjects will investigate the effect of nicotine on arousal, cognitive task and social cognition after acute dose administration.
- Trial name
- NCT01181934
- Testing
- A643 (nicotine)
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Cognitive Dysfunction, Schizophrenia
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years
This first-in-human clinical trial with a randomized, double-blind, placebo-controlled, dose-escalation study design is regarded as standard to test the safety, tolerability, and pharmacokinetics of KYN-5356.
- Trial name
- NCT06225115
- Testing
- KYN-5356
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Kynexis B.V.
Risk Behavior, Cognitive Decline
Intervention on Modifiable Lifestyle Risk Factors for Dementia Prevention
The overarching aim is to develop and deploy a multidomain intervention delivered on a mobile application to help older adults reduce their risk for dementia by improving a set of modifiable lifestyle risk factors associated with…
- Trial name
- NCT04616794
- Testing
- Cognitive Engagement Group, Physical Activity Group, Diet Group
- Where
- Canada
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- LuciLab